Some plaques refuse to be psoriasis or eczema. Ill-defined edges, thin rather than thick scale, excoriation, and itch out of proportion to the plaque are the combination that should stop you committing early — and biopsy in these cases often reports mixed features rather than settling the question, which is a finding rather than a failure.
The practical error is to force a label and then treat with a highly targeted drug that only addresses one immune axis. A patient with dual type 2 and type 3 inflammation put on an IL-17 inhibitor may partially improve and then stall, and the stall gets read as loss of response rather than as a wrong-axis choice.
So when the histology is mixed and the phenotype is ambiguous, document that explicitly in the notes, avoid asserting a diagnosis you do not have, and let the choice of systemic reflect the uncertainty — a broader mechanism is more defensible than a narrow one aimed at a diagnosis you cannot make.
- Record 'overlapping features' honestly rather than picking a label the findings do not support
- Read a mixed biopsy report as information about the disease, not as an inadequate specimen
- Reconsider the diagnosis when a targeted biologic gives partial then stalled improvement
- Photograph and document morphology at baseline so partial response can actually be judged later
- Ask about itch severity separately from plaque appearance — the mismatch is the clue
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free